|1.||Freund, K Bailey: 7 articles (08/2015 - 09/2009)|
|2.||Bandello, Francesco: 4 articles (01/2013 - 01/2010)|
|3.||Cooney, Michael J: 3 articles (04/2012 - 09/2009)|
|4.||de Groot, John F: 3 articles (07/2011 - 09/2008)|
|5.||Zweifel, Sandrine A: 3 articles (03/2011 - 11/2009)|
|6.||Spaide, Richard F: 3 articles (03/2011 - 09/2009)|
|7.||Battaglia Parodi, Maurizio: 3 articles (01/2010 - 01/2010)|
|8.||Iacono, Pierluigi: 3 articles (01/2010 - 01/2010)|
|9.||Kerbel, Robert S: 3 articles (08/2009 - 05/2002)|
|10.||Maruyama, Shoichi: 2 articles (09/2015 - 08/2015)|
|1.||Macular Degeneration (Age-Related Maculopathy)
01/01/2015 - "Studies in patients with age-related macular degeneration have yielded good visual gains without progression of neovascular disease or increased need for intravitreal antivascular endothelial growth factor therapy. "
12/01/2013 - "Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review."
11/01/2013 - "Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration."
11/01/2013 - "Unlike typical age-related macular degeneration, posterior VMA was not associated with a visual outcome after intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy."
03/18/2013 - "Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated?"
01/01/2014 - "The use of antivascular endothelial growth factor in the management of cuticular drusen-associated choroidal neovascularization seems to be an effective method of treatment showing both resolution of optical coherence tomography changes and improvement in visual acuity in this case. "
01/01/2012 - "Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy."
08/01/2010 - "Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization."
01/01/2010 - "In recent years, several case reports and case series have shown that intravitreal injections of antivascular endothelial growth factor drugs can be effective in treating subfoveal choroidal neovascularization secondary to chorioretinal dystrophies either improving vision, or at least halting its progressive loss. "
03/01/2011 - "In six of the seven eyes with a history of choroidal neovascularization controlled with antivascular endothelial growth factor injections, there were areas of subretinal fluid that were not contiguous with the choroidal neovascularization and did not seem responsive to antivascular endothelial growth factor injections. "
11/01/2014 - "Although antivascular endothelial growth factor a (VEGFa) treatment has been well applied in cervical cancer therapy, the underlying molecular basis has not been precisely identified. "
01/01/2013 - "MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer."
01/01/2010 - "Antivascular endothelial growth factor therapy already plays an important role in the management of irradiation complications in tumor eyes."
05/01/2007 - "Moreover, destruction of established tumor mass by treatment with an antivascular endothelial growth factor antibody was markedly enhanced in Cnn1-deficient mice. "
06/01/2004 - "Molecular mechanisms play a role in the pathophysiology, including abnormalities of tumor endothelium, vascular endothelial growth factor and leukotriene synthase. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2015 - "The aim of this article was to review the recent literature on potential therapeutic strategies for overcoming resistance to antivascular endothelial growth factor drugs in ovarian cancer. "
02/01/2015 - "Although clinical benefits of antivascular endothelial growth factor therapy were observed in ovarian cancer treatment trials, this use yielded only modest improvement in progression-free survival and, with the exception of cediranib, no effect on overall survival. "
09/01/2013 - "Angiogenesis has been validated as a target in ovarian cancer through four randomized trials that have reported improved progression-free survival (PFS) in patients with ovarian cancer whose conventional treatment was supplemented with concurrent and maintenance administration of the antivascular endothelial growth factor (VEGF) antibody, bevacizumab. "
07/01/2006 - "The study was undertaken to determine the safety and efficacy of the monoclonal, antivascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with platinum-refractory ovarian cancer. "
04/10/1998 - "The potential of growth, invasion and metastasis of ovarian cancer cells associated with neovascularization, and the expression of platelet-derived endothelial growth factor (PD-ECGF) and its mRNA in ovarian cancers were determined. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
10/01/2006 - "The major clinical trials that have examined antivascular endothelial growth factor agents to treat patients with advanced colorectal cancer will then be described. "
10/01/2006 - "Finally, there is a commentary regarding the status of targeted agents currently in development for the treatment of advanced colorectal cancer and a discussion of the potential future considerations for the use of antivascular endothelial growth factor agents in clinical practice."
02/01/2005 - "Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer."
02/20/2005 - "Although some of the results of combination trials are controversial, recent positive outcomes with an antivascular endothelial growth factor antibody combined with chemotherapy as front-line therapy of metastatic colorectal cancer have renewed enthusiasm for this therapeutic strategy. "
01/01/2012 - "The prognosis of patients with metastatic colorectal cancer in recent years has increased from 5 months with best supportive care to nearly 2 years with chemotherapy combined with bevacizumab, an antivascular endothelial growth factor monoclonal antibody. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|10.||Adrenal Cortex Hormones (Corticosteroids)
|1.||Drug Therapy (Chemotherapy)
|4.||Photochemotherapy (Photodynamic Therapy)